Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewRas-Net (Elk-3) pathway inhibitor (IC50 = 10 - 20 nM). Indirectly inhibits Net phosphorylation upstream of Erk1/2 activation. Mediates G2-M cell cycle arrest, suppresses growth of multiple cell types (IC50 ~ 2 nM), inhibits angiogenesis and acts as a microtubule depolymerizing agent in vitro.
分子量 | 380.87 |
公式 | C21H21ClN4O |
储存 | Store at RT |
纯度 | ≥99% (HPLC) |
CAS Number | 729605-21-4 |
PubChem ID | 10339779 |
InChI Key | NPHPNBGYPKBDDB-UHFFFAOYSA-N |
Smiles | CC1=NN(C2=CC=CC=C2)C(C(N3CCN(C4=CC(Cl)=CC=C4)CC3)=O)=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Wasylyk et al (2008) Inhibition of the Ras-Net (Elk-3) pathway by a novel pyrazole that affects microtubules. Cancer Res. 68 1275 PMID: 18316589
关键词: XRP44X, XRP44X supplier, Ras-Net, pathway, inhibitors, inhibits, Antiangiogenics, microtubule, depolymerization, depolymerisation, agent, MAPK, Signaling, Signalling, G, Proteins, Small, Mitogen-Activated, Protein, Kinases, Tau, Tubulin, Microtubules, Other, Mitosis, Ras, GTPases, 3101, Tocris Bioscience
目前没有该产品的评论。 Be the first to review XRP44X and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
Written by Kirsten L. Bryant, Adrienne D. Cox and Channing J. Der, this review provides a comprehensive overview of RAS protein function and RAS mutations in cancer. Key signaling pathways are highlighted and therapeutic vulnerabilities are explored. This review also includes a detailed section on RAS drug discovery and targeting synthetic lethal interactors of mutant RAS. Compounds available from Tocris are listed.
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.